J Wiegand

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Sajid Khan, Xuan Zhang, Dongwen Lv et al. · Nature Medicine · 2019 · 647 citations · Full text

Medicine, Oncology, Pharmacology +7

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Yonghan He, Xuan Zhang, Jianhui Chang et al. · Nature Communications · 2020 · 257 citations · Full text

Medicine, Molecular Medicine, Pharmacology +13

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Yonghan He, Raphael Koch, Vivekananda Budamagunta et al. · Journal of Hematology & Oncology · 2020 · 131 citations · Full text

Medicine, Cancer Biology, Oncology +14

A comparison of the iron-clearing properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine

RJ Bergeron, RR Streiff, J Wiegand et al. · Blood · 1992 · 76 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +7

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216

Dinesh Thummuri, Sajid Khan, Patrick W. Underwood et al. · Molecular Cancer Therapeutics · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacology +16